The landscape of glucose-lowering therapy and cardiovascular outcomes

From barren land to metropolis

Mona P. Nasrallah, Charbel Abi Khalil, Marwan M. Refaat

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner.

Original languageEnglish
Article number9257930
JournalBioMed Research International
Volume2017
DOIs
Publication statusPublished - 1 Jan 2017

Fingerprint

Glucose
Pharmaceutical Preparations
Drug Approval
United States Food and Drug Administration
Hypoglycemic Agents
Health Personnel
Heart Diseases
Industry
Hospitalization
Therapeutics
Heart Failure
Health
Guidelines
Insulin
Safety
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

The landscape of glucose-lowering therapy and cardiovascular outcomes : From barren land to metropolis. / Nasrallah, Mona P.; Abi Khalil, Charbel; Refaat, Marwan M.

In: BioMed Research International, Vol. 2017, 9257930, 01.01.2017.

Research output: Contribution to journalReview article

@article{72047d37942542c4b36f941b87560df7,
title = "The landscape of glucose-lowering therapy and cardiovascular outcomes: From barren land to metropolis",
abstract = "The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner.",
author = "Nasrallah, {Mona P.} and {Abi Khalil}, Charbel and Refaat, {Marwan M.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/9257930",
language = "English",
volume = "2017",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The landscape of glucose-lowering therapy and cardiovascular outcomes

T2 - From barren land to metropolis

AU - Nasrallah, Mona P.

AU - Abi Khalil, Charbel

AU - Refaat, Marwan M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner.

AB - The choice of glucose-lowering therapy (GLT) has expanded to include 11 different classes in addition to insulin. Since the 2008 Food and Drug Administration guidance for industry and mandate of demonstrating cardiovascular (CV) safety prior to any new drug approval, there were several trials primarily conducted to establish that goal. Some had neutral effects, while there were positively beneficial outcomes with more recent studies. Hospitalization for congestive heart failure has also been a heterogeneous finding among the different classes of GLT, with drug outcomes ranging from risky to beneficial. The current review selectively focuses on the evidence for CV outcomes for each class of GLT and summarizes the existing guidelines with regard to these drugs in heart disease. Moreover, it illustrates the dynamic status in the development of evidence. Finally, the review enables healthcare providers to formulate a plan for hypoglycemic therapy which will optimize CV health, in a patient-centered manner.

UR - http://www.scopus.com/inward/record.url?scp=85042372405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042372405&partnerID=8YFLogxK

U2 - 10.1155/2017/9257930

DO - 10.1155/2017/9257930

M3 - Review article

VL - 2017

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 9257930

ER -